Vasostenone concentrate for the preparation of solution for infusion for intravenous/arterial 20 µg/ml amp 1 ml N 10
Active substance: alprostadil (alprostadil)
pharmachologic effect
Prostaglandin E1 preparation.
Improves microcirculation and peripheral circulation, has an angioprotective effect. When administered systemically, it causes relaxation of smooth muscle fibers, has a vasodilating effect, reduces peripheral vascular resistance, and lowers blood pressure. In this case, there is a reflex increase in cardiac output and heart rate. Improves the rheological properties of blood, helping to increase the elasticity of red blood cells and reducing platelet aggregation and neutrophil activity, increases the fibrinolytic activity of the blood. It affects metabolism, increases the utilization of glucose and oxygen, suppresses the release of free radicals and lysosomal enzymes from granulocytes and macrophages, stimulates protein synthesis, has a beneficial effect on lipid metabolism (suppressing cholesterol synthesis and reducing LDL concentration), and inhibits the proliferation of smooth muscle cells.
Has a stimulating effect on the smooth muscles of the intestines, bladder, and uterus; suppresses the secretion of gastric juice.
When administered intracavernosally, it blocks α1-adrenergic receptors in the tissues of the penis, has a relaxing effect on the smooth muscles of the cavernous bodies, increases blood flow and improves microcirculation. Dilation of the cavernous arteries and vessels of the trabecular smooth muscle of the cavernous bodies leads to a rapid increase in blood flow and dilatation of the lacunar spaces in the cavernous bodies. Venous outflow through the vessels located under the tunica albuginea is limited, which stimulates the development of an erection (“corporal veno-occlusive mechanism”). Onset of action is 5-10 minutes, duration is 1-3 hours.
Dosage regimen
Individual, depending on the indications and dosage form used.
Use during pregnancy and breastfeeding
Alprostadil is contraindicated during pregnancy and lactation (breastfeeding).
Use for liver dysfunction
Contraindications: liver dysfunction, liver disease (including history).
Use in children
In newborns, it should be used under constant blood pressure monitoring, with mandatory conditions for mechanical ventilation.
There is currently no experience with intracavernosal administration in patients under 18 years of age.
Use in elderly patients
There is currently no experience with intracavernosal administration in patients over 75 years of age.
Use IV and IV with caution in case of extensive vascular lesions in diabetes mellitus (in elderly patients).
Vasostenon®
The drug Vasostenon® should be used only as prescribed and under the supervision of doctors with the necessary qualifications who have the ability to constantly monitor the activity of the patient’s cardiovascular system.
Recommended dilution of the drug Vasostenon®, concentrate for the preparation of solution for infusion
The drug Vasostenon® is intended for intra-arterial or intravenous administration in the form of a solution.
The solution must be prepared immediately before the infusion under aseptic conditions. It is recommended to use the solution immediately after preparation; temporary storage of the resulting solution is possible for no more than 24 hours at a temperature of 2-8 °C.
Direct contact of the concentrate with plastic surfaces should be avoided. Therefore, it is recommended to introduce the concentrate into the prepared sodium chloride solution to avoid contact with the walls of the container.
Intra-arterial administration
Dissolve the contents of one ampoule of Vasostenon® (corresponding to 20 mcg of alprostadil) in 50 ml of isotonic 0.9% sodium chloride injection solution.
In the absence of other prescriptions, the contents of half an ampoule of the drug Vasostenon® (corresponding to 10 mcg of alprostadil) should be administered intra-arterially over 60-120 minutes. when using an infusion device. If necessary, especially in the presence of necrosis, under strict control of drug tolerance, the dose can be increased to one ampoule (corresponding to 20 mcg of alprostadil). This dosage is usually used as a single daily infusion.
If intra-arterial infusion is carried out through an inserted catheter, depending on tolerability and severity of the disease, a dose of 0.1-0.6 ng/kg/min is recommended. with administration of the drug over 12 hours (corresponds to 1/4 - 1½ ampoules of the drug Vasostenon®).
Intravenous administration
Dissolve the contents of two ampoules of the drug Vasostenon® (corresponding to 40 mcg of alprostadil) in 50-250 ml of isotonic 0.9% sodium chloride injection solution and administer the prepared solution intravenously for 2 hours. This dose is applied twice daily.
Or the contents of three ampoules of Vasostenon® (60 mcg alprostadil), diluted in 50-250 ml of isotonic 0.9% sodium chloride injection solution, administered intravenously over 2 hours once a day.
In patients with impaired renal function (serum creatinine concentration more than 1.5 mg/dL)
intravenous administration of the drug Vasostenon® begins with 20 mcg (1 ampoule), administered over 2 hours. If necessary, after 2-3 days a single dose (corresponding to 20 mcg of alprostadil) is increased to 40-60 mcg.
For patients with renal failure or patients who may be considered at risk due to impaired cardiac function, the volume of fluid administered during infusion should be limited to 50-100 ml per day to avoid the appearance of symptoms of overhydration. Infusion should be carried out using infusion pumps.
The duration of therapy is on average 14 days; if the therapeutic effect is positive, treatment with the drug can be continued for another 7-14 days. The course of treatment should not exceed 3-4 weeks. If there is no positive effect within 2 weeks from the start of treatment, further use of the drug should be discontinued.
The clinical effect is long-term and may appear with a certain delay after the end of the course of treatment.
Brief instructions for use of the drug Vasostenon
The use of Vasostenone is indicated in the presence of chronic diseases of the peripheral arteries in adult patients. This drug has a number of contraindications, among which are the following:
- sensitivity to the components of the product;
- the presence of diseases or disorders of the heart;
- suspected pulmonary edema;
- liver disease, renal dysfunction;
- bleeding of various origins in the digestive organs;
- stroke, arterial hypotension in severe stages;
- chronic lung diseases;
- pregnancy, lactation, childhood.
Before using Vasostenone, you should read its description, because in combination with certain medications, the effectiveness of treatment may vary. You should also familiarize yourself with the peculiarities of using Vasostenone, described in the instructions for it. This medication is administered intravenously or intra-arterially with a special syringe, infusion pump or catheter.
The dosage of the drug is calculated by the doctor in accordance with the age and health status of the patient. At the beginning of the therapeutic course, it is advisable to use the minimum dose of the drug, increasing it gradually if no negative reaction is observed. Vasostenone has many positive reviews due to the effectiveness it has on the body when treated correctly.
When treating with this pharmaceutical drug, it is important to strictly adhere to the prescribed dosage, since its exaggeration can cause adverse reactions from the nervous, respiratory, cardiovascular, digestive and other systems of the body.
The cost of Vasostenone is high, therefore, before purchasing it, it is advisable to make sure that the patient does not have any allergic reactions to this medication or is individually intolerant to it. You cannot choose cheaper analogues of Vasostenone without first consulting a doctor, since an incorrectly selected drug can significantly worsen a person’s health.
Vasostenone
Compound:
active ingredient: alprostadil;
1 ampoule contains 20 mcg of alprostadil;
excipients: ethanol.
Dosage form: concentrate for the preparation of solution for infusion.
Basic physical and chemical properties: colorless transparent solution without mechanical impurities.
Pharmacotherapeutic group: Prostaglandins. ATS code C01E A01.
Alprostadil, the active substance of the drug VAZOSTENON , is a vasodilator.
It increases blood flow by dilating arterioles and precapillary sphincters.
Alprostadil improves microcirculation and rheological abilities of the blood.
After intravenous use in healthy volunteers and patients, an increase in the elasticity of erythrocytes and inhibition of their aggregation ex vivo is observed.
Alprostadil effectively inhibits platelet activation in vitro.
This effect also extends to the shape, aggregation, secretion of substances contained in the granules, and the release of thromboxane, a substance that promotes aggregation.
The drug leads to a reduction in the incidence of arterial blood clots.
| UVAGA: ILLEGAL IMPORTATION DO NOT REGISTER A DOCTOR'S THANKS! |
The company with the interconnected name "VALARTIN PHARMA", which is the only official distributor registered in Ukraine, is ahead of having entered the pharmaceutical market of Ukraine There is no registration of medicinal drug under the similar name “VASOSTENON”, which is illegal, because violation of legislation, imports from the Russian Federation .
In Ukraine, the medical prescription “VASOSTENON” was re-registered by the Order of the Ministry of Health dated December 22, 2020. No. 2970, Registration information No. UA/14734/01/01, issuer and applicant for the medical service - company AT "KEVELT", Estonia.
Labeling of packages of the legal medicinal product "VAZOSTENON" in the Ukrainian language, the skin packaging should be accompanied by Ukrainian instructions and sent to the registration number in Ukraine .
The skin series of the registered medicinal product “VASOSTENON”, which is supplied by LLC “VALARTIN PHARMA” in the territory of Ukraine, is accompanied by a Certificate of Vibrator and Visnovk’s virility about the virility of the medicinal product imported to Ukraine, issued by the Powers by the new service of Ukraine for medicinal purposes and drug control, on the basis of the results of the sovereign input luminosity control. Submitted documents for the support of a companion may be given by a pharmacy deposit.
Labeling of packages of the unregistered medicinal product “VAZOSTENON”, which is illegally imported from the Russian Federation, vikonana Russian, packaging of the drug is accompanied by Russian instructions , the registration authority is additionally indicated on the packaging in the instructions ійного позіденья — “PJSC “Pharmsintez”, Russia, Leningrad region, Vsevolozhsk district -n, mountains village Kuzmolovsky, st. Kapitolovo, No. 134, letter 1." The registration number of the Russian Federation is indicated.
The design of the “Russian” packaging is similar to the design of a legal drug registered in Ukraine, which can be misled by fellow residents.
I LOVE YOUR RESPECT!!!
- Regular legislation has prohibited of unregistered medicinal products on the territory of Ukraine
- The government authority in the field of medicinal products - the State Service of Ukraine for medicinal products and drug control - warns about the need to add medicinal products to the subjects of government with a special license and to explicit documents that confirm the quality of the medical profession.
- The medicinal drug “VASOSTENON” requires a special temperature regime during transportation and storage (store in the refrigerator at a temperature of 2° to 8° C). Failure to adjust the temperature regime can result in a toxic influx on the fluid and safety of the medicinal product during medical treatment, which can pose a threat to the life and health of patients.
- In the case of illegally imported substances, it is impossible to monitor and guarantee the maintenance of the species' minds, transportation and conservation of medical supplies, which can lead to unnecessary side reactions when it is frozen and can lead to a threat to health and life.
- The medicinal drug “VAZOSTENON” is stagnant in life-threatening conditions, so safety in case of stagnation may be a must.
Individuals who are engaged in illegal (illegal) transportation through the border cordon of Ukraine of the medicinal company "Vasostenon" from the Russian Federation, which is not registered in Ukraine and has not passed the government's entry control in Ukraine, harm Ukrainian associates to the detriment of bake and actually do not bear any responsibility for the acidity, the safety and effectiveness of this drug, as well as its actual similarity. Even the rest may be falsified !
BE HAPPY!
The acquisition of medicinal products unregistered in Ukraine “from hand” and through the Internet leads to the risk of falsified medicinal products. Do not let the life and health of your loved ones become unsafe, even in critical situations this can lead to fatal consequences!
More about the product:
- Instructions for medical use of the drug VAZOSTENON
- Registration certificate
Description of the drug VASOSTENOON
Use IV and IV with caution in acute and subacute myocardial infarction, in myocardial infarction suffered within the last 6 months, in severe or unstable angina, decompensated chronic heart failure, in arterial hypotension, cardiovascular failure, in pulmonary edema, severe arrhythmias, broncho-obstructive syndrome (severe with signs of respiratory failure), with infiltrative changes in the lungs, liver failure (including a history), with an increased risk of bleeding (including gastric ulcer or duodenum, severe damage to cerebral vessels, proliferative retinopathy with a tendency to bleeding, extensive trauma), hemodialysis, type 1 diabetes, especially with extensive vascular damage (in elderly patients); against the background of the use of vasodilators or anticoagulants; in newborns (risk of developing bradypnea, arterial hypotension, tachycardia or hyperthermia).
Use intracavernosally with caution in case of thrombocytopenia, polycythemia, thrombophlebitis, venous thrombosis (including in case of predisposition), increased blood viscosity, balanitis, urethritis.
Should not be used in patients with a tendency to drug addiction and/or mental or intellectual disorders.
In case of disorders of the blood coagulation system or during simultaneous treatment with drugs that affect the coagulation system, blood coagulation parameters should be regularly monitored during treatment with alprostadil. With systemic administration, monitoring of central hemodynamic parameters and biochemical blood parameters is necessary.
With long-term continuous administration, apnea may develop, a negative effect on the structure of the wall of the ductus arteriosus with an increased risk of rupture, and thinning of the muscular layer of the pulmonary artery. With a treatment duration of more than 4 weeks, reversible cortical proliferation of tubular bones is possible.
In newborns, it should be used under constant blood pressure monitoring, with mandatory conditions for mechanical ventilation.
There is currently no experience with intracavernosal administration to patients under 18 years of age and over 75 years of age.
Alprostadil is not intended for simultaneous use with other drugs for the treatment of erectile dysfunction.
The compliance of the dosage form of alprostadil used with the specific indications for its use should be strictly observed.
